Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
CASI
#3957
CASI Pharmaceuticals, Inc. Ordinary Shares
0.2
1
-73.75%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-73.75%
Changement Mensuel
-78.79%
Evolution sur 6 mois
-90.41%
Changement Annuel
-91.36%
Clôture Précédente
0.8
0
Open
0.2
1
Bid
Ask
Low
0.2
1
High
0.2
1
Volume
17
Marchés
Actions des Marchés US
Soins de Santé
CASI
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2022
2023
2024
Total assets
96.23 M
75.27 M
53.67 M
Total liabilities
29.3 M
51.1 M
51.82 M
Total equity
44.57 M
24.16 M
1.85 M
Total liabilities & shareholders' equities
96.23 M
75.27 M
53.67 M
Total debt
—
—
—
Net debt
—
—
—
Nouvelles
What Drove CASI Pharmaceuticals' 24% Rise After Hours? - CASI Pharmaceuticals (NASDAQ:CASI)
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
Il titolo CASI Pharmaceuticals crolla dopo la notifica di delisting dal Nasdaq
CASI Pharmaceuticals stock plunges on Nasdaq delisting notice
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection
Il titolo CASI Pharmaceuticals balza dopo la proroga del Nasdaq
CASI Pharmaceuticals ottiene proroga per la quotazione al Nasdaq fino a febbraio 2026
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026
CASI Pharmaceuticals secures $20 million funding for transplant rejection study